Table 1.
Clinicopathological characteristics of 143 clear cell renal cell carcinoma cases according to FPN and FBXL5 expression status
| Variable | No. of cases (n=143) | FPN expression | FBXL5 expression | ||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| High (n=72) | Low (n=71) | p-value | High (n=58) | Low (n=85) | p-value | ||
| Age (yr) | 60.2±12.0 | 59.1±11.7 | 0.581 | 60.4±11.3 | 59.2±12.2 | 0.529 | |
|
| |||||||
| Tumor size (cm) | 9.12±4.00 | 9.06±3.42 | 0.930 | 9.18±3.65 | 9.03±3.76 | 0.804 | |
|
| |||||||
| Sex | |||||||
|
| |||||||
| Female | 40 | 23 (31.9) | 17 (23.9) | 0.287 | 16 (27.6) | 24 (28.2) | 0.932 |
|
| |||||||
| Male | 103 | 49 (68.1) | 54 (76.1) | 42 (72.4) | 61 (71.8) | ||
|
| |||||||
| Nuclear grade | |||||||
|
| |||||||
| 2 | 25 | 14 (19.4) | 11 (15.5) | 0.534 | 4 (6.9) | 21 (24.7) | 0.006 |
|
| |||||||
| 3 and 4 | 118 | 58 (80.6) | 60 (84.5) | 54 (93.1) | 64 (75.3) | ||
|
| |||||||
| Perirenal fat invasion | |||||||
|
| |||||||
| Absent | 67 | 30 (41.7) | 37 (52.1) | 0.211 | 28 (48.3) | 39 (45.9) | 0.778 |
|
| |||||||
| Present | 76 | 42 (58.3) | 34 (47.9) | 30 (51.7) | 46 (54.1) | ||
|
| |||||||
| Sinus fat invasion | |||||||
|
| |||||||
| Absent | 59 | 31 (43.1) | 28 (39.4) | 0.660 | 21 (36.2) | 38 (44.7) | 0.311 |
|
| |||||||
| Present | 84 | 41 (56.9) | 43 (60.6) | 37 (63.8) | 47 (55.3) | ||
|
| |||||||
| Vascular invasion | |||||||
|
| |||||||
| Absent | 80 | 44 (61.1) | 36 (50.7) | 0.210 | 28 (48.3) | 52 (61.2) | 0.127 |
|
| |||||||
| Present | 63 | 28 (38.9) | 35 (49.3) | 30 (51.7) | 33 (38.8) | ||
|
| |||||||
| Sarcomatoid/Rhabdoid differentiation | |||||||
|
| |||||||
| Absent | 128 | 66 (91.7) | 62 (87.3) | 0.397 | 53 (91.4) | 75 (88.2) | 0.547 |
|
| |||||||
| Present | 15 | 6 (8.3) | 9 (12.7) | 5 (8.6) | 10 (11.8) | ||
|
| |||||||
| Necrosis | |||||||
|
| |||||||
| Absent | 122 | 62 (86.1) | 60 (84.5) | 0.786 | 49 (84.5) | 73 (85.9) | 0.816 |
|
| |||||||
| Present | 21 | 10 (13.9) | 11 (15.5) | 9 (15.5) | 12 (14.1) | ||
|
| |||||||
| STAT3 expression | |||||||
|
| |||||||
| Low | 117 | 55 (76.4) | 62 (87.3) | 0.090 | 42 (72.4) | 75 (88.2) | 0.016 |
|
| |||||||
| High | 26 | 17 (23.6) | 9 (12.7) | 16 (27.6) | 10 (11.8) | ||
|
| |||||||
| Recurrence/Metastasis | |||||||
|
| |||||||
| Absent | 54 | 32 (44.4) | 22 (31.0) | 0.097 | 25 (43.1) | 29 (34.1) | 0.276 |
|
| |||||||
| Present | 89 | 40 (55.6) | 49 (69.0) | 33 (56.9) | 56 (65.9) | ||
|
| |||||||
| Survival | |||||||
|
| |||||||
| Alive | 86 | 50 (69.4) | 36 (50.7) | 0.022 | 43 (74.1) | 43 (50.6) | 0.005 |
|
| |||||||
| Expired | 57 | 22 (30.6) | 25 (49.3) | 15 (25.9) | 42 (49.4) | ||
Values are presented as mean±SD or number (%). FBXL5, F-Box and leucine rich repeat protein 5; FPN, ferroportin; STAT3, signal transducer and activator of transcription 3.